Hyperhomocysteinaemia is assocaited with uveitis but not with deep venous thrombosis in Behçet's disease

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 12, 2004, Pages 1417-1423

  Feki, Moncek ^a   Houman, Habib ^a   Ghannouchi, Mehdi ^a   Smiti Khanfir, Monia ^a   Hamzaoui, Kamel ^b   El Matri, Leila ^a,c   Mebazaa, Abderraouf ^a   Kaabachi, Neziha ^a  

^a LA RABTA HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^c Institute of Ophthalmology   (Tunisia)

Author keywords

Beh et's disease; Deep venous thrombosis; Endothelial dysfunction; Homocysteine; Oxidant stress; Retinal vasculitis; Uveitis

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP;

ADULT; AGE; ARTHRITIS; ARTICLE; AUTOANALYSIS; BEHCET DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLIC ACID BLOOD LEVEL; GENDER; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UVEITIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ADOLESCENT; AGED; BLOOD; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; MIDDLE AGED; TUNISIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; BEHCET SYNDROME; COHORT STUDIES; COMORBIDITY; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PREVALENCE; TUNISIA; UVEITIS; VENOUS THROMBOSIS;

EID: 11244283250     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.263     Document Type: Article

References (55)

1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
2. Yazici H. Behçet's syndrome: where do we stand? Am J Med 2002;112:75-6.
3. Zouboulis CC. Epidemiology of Adamantiades-Behçet's disease. Ann Intern Med 1999;150:488-98.
4. O'Duffy JD. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 1990;16:423-31.
5. Lie JT. Vascular involvement in Behçet's disease: arterial and venous and vessels of all sizes. J Rheumatol 1992;19:341-3.
6. Zierhut M, Saal JG, Pleyer U, Kotter I, Durk H, Fierlbeck G. Behçet's disease, epidemiology and eye manifestations in German and Mediterranean patients. Ger J Ophthalmol 1995;4:246-51.
7. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14:67-79.
8. Atmaca LS, Sonmez PA. Fluorescein and indocyanine green angiography findings in Behçet's disease. Br J Ophthalmol 2003;87:1466-8.
9. 2a: a pilot study. Br J Ophthalmol 1998;82:488-94.
10. Whallett AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI. Behçet's syndrome: a multidisciplinary approach to clinical care. Q J Med 1999;92:727-40.
11. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;34:1284-91.
12. Houman MH, Ben Ghorbel I, Khiari-Ben Salah I, Lamloum M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behçet's disease. Clin Exp Rheumatol 2001;19(Suppl 24):S48-50.
13. Chambers JC, Haskar DO, Kooner JS. Vascular endothelial function and oxidative stress mechanism in patients with Behçet's syndrome. J Am Coll Cardiol 2001;37:517-20.
14. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57.
15. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
16. Cahilla M, Karabatzakia M, Meleadyb R, Refsum H, Ueland P, Shield D, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000;84:154-7.
17. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136:1136-50.
18. Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 1999;83:1287-90.
19. Faraci FM. ATVB in focus: endothelium: signalling, oxidative stress, and gene expression. Arterioscler Thromb Vasc Biol 2003;23:728.
20. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-80.
21. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-5.
22. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, Weinberger A. Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 2001;28:1033-6.
23. Altinbas A, Aytemur K, Tokgozoglu L, Ozturk M, Kosar A, Hazendarouglu IC, et al. Hyperhomocysteinemia and activated protein C resistance in Behçet's disease. J Intern Med 2000;248:267-9.
24. Aksu K, Turgan N, Oksel F, Keser G, Ozmen D, Kitapçioglu G, et al. Hyperhomocysteinaemia in Behçet's disease. Rheumatology (Oxford) 2001;40:687-90.
25. Er H, Evereklioglu C, Cumurcu T, Turkoz Y, Ozeral E, Sahin K, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002;86:653-7.
26. Korkmaz C, Bozan B, Kosar M, Sahin F, Guldbar Z. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? Clin Exp Rheumatol 2002;20(Suppl 4):S30-4.
27. Ates A, Aydintug O, Olmez U, Duzgun N, Duman M. Serum homocysteine level is higher in Behçet's disease with vascular involvement. Rheumatol Int 2003 (online first).
28. Yesilova Z, Pay S, Oktenli C, Musabak U, Saglam K, Sanisoglu SY, et al. Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy? Rheumatol Int 2004 (online first).
29. Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, et al. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res 2002;106:19-24.
30. Calikoglu E, Oztas M, Sengul N, Adam B, Gurer MA. Serum homocysteine level in Behçet's disease. Haematologia (Budap) 2002;32:219-24.
31. Bekpinar S, Kocak H, Unlucerci Y, Genc S, Akdag-Kose A, Gogus F. The evaluation of C-reactive protein, homocysteine and vitamin B6 concentrations in Behçet and rheumatoid arthritis disease. Clin Chim Acta 2003;329:143-5.
32. Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease. Rheumatol Int 2003;23:236-40.
33. Okka M, Ozturk M, Korkar MC, Bavbek N, Rasier Y, Gunduz K. Plasma homocysteine level and uveitis in Behçet's disease. Isr Med Assoc J 2002;4(Suppl):S931-4.
34. Toydemir PB, Elhan AH, Tukun A, Toydemir R, Gurler A, Tuzuner A, et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. J Rheumatol 2000;27:2849-54.
35. Kiraz S, Ertenli I, Ozturk MA, Hazendaroglu IC, Celik I, Calguneri M. Pathological haemostasis and "prothrombotic state" in Behçet's disease. Thromb Res 2002;105:125-33.
36. Ozoran K, Dugun N, Gurler A, Tutkak H, Tokgoz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995; 24:376-82.
37. Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV, Kirazli S. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Intern Med 1996;24:181-7.
38. Orem A, Yandi YE, Vanizor B, Cimsit G, Uydu HA, Malkoc M. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. Clin Biochem 2002;35:217-24.
39. Duzgun N, Ayaslioglu E, Tutkak H, Sahin M, Aydintug O, Olmez U. Plasma thrombomodulin levels in patients with Behçet's disease. Rheumatol Int 2003;23:130-3.
40. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993;52:659-66.
41. Freitas JP, Filipe P, Yousefi A, Emerit I, Guerra Rodrigo F. Oxidative stress in Adamantiades-Behçet's disease. Dermatology 1998;197:343-8.
42. Noyan T, Sahin I, Sekeroglu MR, Dulger H. The serum vitamin C levels in Behçet's disease. Yonsei Med J 2003;44:771-8.
43. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, Cooke JP, Loscalzo J, et al. Homocysteine impairs coronary microvascular dilator function in humans. J Am Coll Cardiol 2002;40:1051-8.
44. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial function and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002;7:227-39.
45. Jin L, Abou-Mohamed G, Caldwel RB, Caldwel RW. Endothelial cell dysfunction in a model of oxidative stress. Med Sci Monit 2001;7:585-91.
46. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41:1444-54.
47. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-α, NAD(P)H oxidase and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003;23:418-24.
48. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158: 2101-6.
49. Eichinger S, Stumpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.
50. den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med 2003;41:1404-7.
51. Vin AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000;129:640-4.
52. Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye 2000;14:590-3.
53. Brown BA, Marx JL, Ward TP, Hollifield RD, Dick JS, Brozetti JJ, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109:287-90.
54. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002;12:495-500.
55. Blondel J, Glacet-Bernard A, Bayani N, Blacher J, Lelong F, Nordmann JP, et al. [Retinal vein occlusion and hyperhomocysteinemia]. J Fr Ophtalmol 2003;26:249-53.